We describe an adaptation of conventional ELISA methods to an ELISA-Array format using 17 non-contact Piezo printing of up to 30 spots of purified recombinant viral fusion proteins, 18 vaccine and virus on 96 well high-protein binding plates. Antigens were printed in 1 nanoliter 19 volumes of protein stabilizing buffer using as little as 0.25 nanograms of protein, 2000-fold less 20 than conventional ELISA. The performance of the ELISA-Array was demonstrated by serially 21 diluting n=8 human post-flu vaccination plasma samples starting at a 1/1000 dilution and 22 printed antigens and analyte matrices the methods of this multiplexed ELISA-Array format can 34 be broadly applied in translational research. 35
measuring binding to the array of Influenza antigens. Plasma polyclonal antibody levels were 23 detected using a cocktail of biotinylated anti-human kappa and lambda light chain antibodies, 24 followed by a Streptavidin-horseradish peroxidase conjugate and the dose-dependent signal was 25 developed with a precipitable TMB substrate. Intra-and inter-assay precision of absorbance units 26 among the eight donor samples showed mean CVs of 4.8% and 10.8%, respectively. The plasma 27 could be differentiated by donor and antigen with titer sensitivities ranging from 1 x 10 3 to 4 x 28 10 6 , IC 50 values from 1 x 10 4 to 9 x 10 6 , and monoclonal antibody sensitivities in the ng/mL 29 range. Equivalent sensitivities of ELISA versus ELISA-Array, compared using plasma and an 30 H1N1 HA trimer, were achieved on the ELISA-Array printed at 0.25ng per 200um spot and 31 1000ng per ELISA 96-well. Vacuum-sealed array plates were shown to be stable when stored for 32 at least 2 days at ambient temperature and up to 1 month at 4-8°C. By the use of any set of 33 INTRODUCTION 36 The activity of humoral antibodies provide the best correlation to long-term immune memory 37 and protection (Antia et al. 2018) . During the first two weeks of exposure to a pathogen, the 38 majority of antibodies found in the serum derive from plasmablasts, either rapidly re-activated 39 from memory B cell pools or expanded from newly stimulated, somatically hypermutated and 40 differentiated B cells upon contact with antigen in lymph tissue (De Silva and Klein 2015) . 41
During recovery, some plasmablasts will home to the bone marrow where they terminally 42 differentiate into long-lived plasma cells stably secreting antibodies that circulate in serum for 43 many years ( The enzyme-linked-immunosorbent-assay (ELISA) first described by Engvall and 57 Perlmann (1972) , is commonly used to measure specific antibody-antigen binding. Variants and 58 derivatives of the ELISA have become assay workhorses of immunology laboratories and a host 59 of compatible reagents, consumables, plate washers, multichannel pipettes, robotic liquid 60 handlers, and assay formats have been developed and are available from multiple vendors. A 61 conventional antigen ELISA single plex format passively coats antigens on a 96-well high 62 capacity protein binding surface (e.g. Nunc Maxisorp™, ThermoFisher Scientific, Waltham, 63 MA) and indirectly titers primary antibody binding by secondary binding of polyclonal 64 antibodies conjugated to horseradish peroxidase (HRP), which turns over the colorimetric 65 3,3',5,5'-tetramethylbenzidine (TMB) substrate for assay readout. Secondary antibodies are 66 typically directed against a constant region of the heavy or light chain of the primary antibody, 67 such as polyclonal anti-Fc directed to IgG, IgM, IgA or IgE, anti-kappa or anti-lambda light 68 chains. A common variation to boost sensitivity includes using a biotinylated secondary antibody 69 with a Streptavidin-horseradish peroxidase (HRP) conjugate. Although fluorescent reporters 70 have the advantage of allowing for multiplexed detection using different dyes, the use of HRP 71 has been shown to be more sensitive because the enzymatic turnover of colorimetric or 72 chemiluminescent substrates amplifies the signal (Gogalic et al. 2018) . 73
The principles of ELISA have been adapted using advances in the protein array field to 74 increase the throughput, efficiency and scope of data in immunoassays (reviewed in Kingsmore 75 2006) . Printing proteins can be carried out by passive adsorption without requiring modification 76 or chemical coupling to nanoparticles or other surfaces. This advantage and advancements in 77 nozzle technology allow for flexibility and precision in spotting picolitre volumes of purified, 78 crude, or complex proteinaceous substrates (Barbulovic-Nad et al. 2006 ). Furthermore, a 79 superior level of sensitivity can be achieved in miniaturized ligand-binding assays, as shown by 80
Ekins' ambient analyte assay theory (Ekins 1989 ). Obtaining higher sensitivity in a system that 81 uses smaller amounts of capture molecules and smaller amounts of sample can be explained by 82 two main features. First, the binding reaction occurs at a high target concentration; and second, 83 the capture-molecule-target complex is found only in the small area of the spot, resulting in a 84 high local signal (Templin et al. 2002 
RESULTS

111
Initial optimization of printing conditions 112
Although many operating conditions for printing followed the standard recommendations of the 113 manufacturer of the sciFLEXARRAYER S12 instrument, several specific parameters were 114 optimized for this ELISA-Array application. We tested variations in printing protein 115 concentration, drop volume and formulation buffer using goat anti-human Fc polyclonal 116 antibody (Jackson ImmunoResearch, West Grove, PA) as a probe with commercially available 117 human reference serum (Bethyl Laboratories, Montgomery, TX) as an analyte. The probe was 118 varied by diluting a PBS stock in a 1:1 volume of each of three sciSPOT protein formulation 119 buffers D1, D11 and D12 (Scienion AG, Berlin, Germany). Probe was dispensed in 1, 2 or 4 120 drops from a 384-well source plate at 25, 100 and 400 ug/mL final. PBS in formulation buffers 121 without the anti-human Fc protein was used for a background control. The probes of the printed 122 arrays bound to the Fc region of IgG within the human plasma, then are detected with HRP 123 conjugate antibodies specific to the kappa light chain of the IgG antibody in a traditional 124 sandwich ELISA format. 125
The signal intensity increased with increasing protein printed, and 400 ug/mL provided 126 the highest signal. The spot size increased with drop number, but the sensitivity was similar 127 between 2 and 4 drops. The protein stabilizing D12 buffer offered the highest sensitivity among 128 formulation buffers to approximately 4 ng/ml concentrations of IgG detected from human sera. 129
These data are shown in Supplementary Figure S1 . The final printing parameters used in this 130 report for Influenza antigens are described in the methods section. Twelve 96-well plates were 131 printed in one batch with the Influenza antigens listed in Table 1 and using the array pattern 132 illustrated in Figure 1 . 133 134
Assay miniaturization gain of sensitivity in ELISA-Array 135
According to the ambient assay theory (Ekins 1989 ), miniaturizing the ELISA to an array print 136 of 0.25ng of protein in a 200um spot (with a surface area of 15.6mm 2 , or 0.02ng/mm 2 ) should 137 yield higher sensitivity than coating in the same proportion over an entire 96-well (with a surface 138 area of 320mm 2 ). We tested this by comparing the signal sensitivity obtained using human 139 immune reference plasma binding purified H1N1 HA trimer, either printed in 0.25ng spots in 140 triplicate or coated in a 96-well at 1000, 100, 10 or 1 ng in duplicate. Following the same assay 141 methods with the exception of the final TMB substrate (soluble for the ELISA and precipitating 142 for the ELISA-Array), equivalent IC 50 values were obtained only when the 96-well was coated 143 with 2000-fold more total protein, or >150-fold more/mm 2 ( Figure 2 ). 144 145
Data analysis 146
After calculating median intensity in absorbance units (AU) of each triplicate set of antigen 147 spots, we fit standard 4-parameter logistic (4P) curves of intensity against plasma or mAb 148 concentration with PRISM (GraphPad, San Diego, CA). In each plate we tested three negative 149 controls to calculate the lower limit of detection, and on average the LOD value was less than 5 150 AU. Because the variance in readings at values less than 10 AU was high (data not shown), we 151 set a lower limit of detection (LLOQ) at 10 AU. From the 4P curves fit to each sample we 152 calculated both the titer at which the curve passed the LLOQ and the IC 50 values. Across our 153 assays we observed that the upper intensity range was never greater than 180 AU and thus set 154 observed in the assay with these mAbs. Specificity was also tested by printing a GFP-foldon-178
Avitag-6His trimer in each well as a negative control protein, at the same concentration as the 179 Influenza A HA trimers. This control showed no binding to donor plasma or to control antibodies 180 mAb A and mAb B. 181
The lack of binding of control mAb A to the HA trimer of A/Shanghai/02/2013 H7N9 182 was not expected based on publications of this mAb binding to other H7 strains of HA, albeit at 183 lower affinities than other HA subtypes (Kallewaard et al. 2016) . Reference plasma and other 184 donor plasma did bind the H7 trimer (Figures 3 and 4) . A repeat test print of the H7 HA trimer at 185 0.5, 0.375 and 0.25ng/spot did not change the binding results, nor did testing on a regular ELISA 186 format (data not shown). Further optimization of this antigen, and comparisons to other strains 187 are needed in order to draw conclusions on cross-reactive antibody binding to H7. 188 189
ELISA-Array assay performance 190
The ELISA-Array assay was qualified using a selected in-house human reference plasma and 191 eight individual human plasma samples from day 28 post-vaccination with the 2018 FluLaval 192 quadrivalent vaccine (GlaxoSmithKline, Research Triangle Park, NC). All array plates used for 193 performance testing were from one print batch, stored at 4ºC. To increase accuracy, we avoided 194 making large dilutions by preparing stock solutions of 10x reference plasma, 10x control mAbs, 195 100x secondary biotinylated antibody mixture, and 100x streptavidin conjugate in assay diluent. 196
These were aliquoted and stored at -80ºC. Each plasma donor was also aliquoted undiluted and 197 stored at -80ºC. Although not done in these assays, it would be optimal in the future to briefly 198 spin down donor plasma before assaying to clear the sample of lipid and other aggregates. 199
Aliquots were freshly thawed for each assay, and the same lot of assay diluent and TMB 200 substrate were also used throughout all assays. The final concentrations of assay materials are 201 described in the methods section. Intra-assay precision was determined by running n=3 plate 202 assays on the first day after printing the arrays. Inter-assay precision was determined by running 203 an additional two plates one and two weeks later. Precision was calculated by the variance 204 between plates of titer and IC 50 values for reference plasma and each of the eight donors for all 205 array antigens. Intra-and Inter-assay precision data is shown for the reference plasma and two 206 donors in Figure 4 , and Tables 3 and 4 
, respectively, and for all eight plasma samples in 207
Supplementary Tables S1 and S2. The precision of absorbance units among the reference plasma 208 and two donors showed mean CV of 4.8% intra-assay and 10.8% inter-assay, and 6.0% intra-209 assay and 12.5% inter-assay among the eight donor samples. There were a few examples of high 210 variance inter-assay, in samples of low dilutions. This may be due to weak binding or 211 interference from the serum matrix. The plasma titers could be differentiated by donor and 212 antigen with sensitivities ranging from 1 x 10 3 to 4 x 10 6 and IC 50 values from 1 x 10 4 to 9 x 10 6 213 ( Figure 4 , Table 4 , and Table S2 ). For example, we measured a robust titer in the reference 214 plasma donor to all array antigens ( Figure 4) . In contrast, robust titers in donor 1 plasma were 215 measured only to the vaccine itself, to Influenza B viruses and to the individual antigens of 216 H1N1 and H3N2 HA trimers matching the strains used in the vaccine (Table 1 and Figure 4) . 217
There was only weak binding to HA trimers not in the vaccine (i.e. H2, H5, H7), indicating 218 insufficient cross-reactive antibodies were elicited in donor 1. A plot of IC 50 values in Figure 5  219 for three donors shows the overall tight standard deviations between three assays performed over 220 three weeks, and visually quantifies differences between antibody binding for each of the array 221 antigens and donors. We cannot differentiate pre-existing antibody immunity from vaccine 222 responses in these samples, but the quantitative nature of the data would allow for this to be done 223 using titer and IC 50 comparisons with pre-vaccine plasma, not included in this study. Three 224 rounds of freeze thaws of the reference plasma from -80ºC showed no change in IC 50 values or 225 titers (data not shown). One plate assay was also run by a second operator to evaluate the 226 robustness of the method, which was determined to be equivalent to intra-assay precision (Plate 227 4 in Figure 6 and Table S3 ). 228 229
Stability testing of printed plates 230
Printed array plates were covered with a foil plate seal and vacuum-sealed immediately after the 231 overnight curing step and stored at 4ºC. They were found to be stable stored in this manner for 232 up to one month ( Figure 6 ). At 8 weeks post-print, plates stored at 4ºC showed about a 2-fold 233 drop in IC 50 and the titer shifted to one higher dilution in the ¼ titration series (i.e. a change from 234 1x10 6 to 2.6 x10 5 ). Significant losses in activity were also measured for vacuum-sealed plates 235 stored for 1 week at either ambient temperature or 37 ºC ( Figure 6 ). All of the stability assay data 236 including variability for each antigen and plasma sample are provided in Supplementary Tables  237   S4 and An ability to print microarrays in a format for a 96-well ELISA-Array was first published by 262 Mendoza et al. (1999) , and its utility for infectious disease testing has been demonstrated with 263 antibody arrays to encephalitis viruses (Kang et al. 2012 ) and viral antigen arrays to Flaviviridae 264 (Wang et al. 2015) , using a non-contact piezo Bio-Dot Printing System (Biodot, Irvine, CA). As 265 with these two prior studies, we printed using non-contact piezo nozzles, but in smaller volumes 266 using a Scienion S12 instrument. We compared binding data in arrays using a variety of 267 Influenza antigen types including recombinant viral protein HA trimers, vaccine and viruses. The 268 parallel identification of viral antigen binding was carried out in a quantitative manner by 269 performing full dose-response curves of human plasma with an analysis of the precision of titer 270 and IC 50 values. These data allowed for a comparison of the abundance and context of antibodies 271 from natural exposure or vaccination within a single individual and between individuals. In 272 future arrays it would be of interest to include the Influenza neuramidase protein, a second viral 273 surface protein that can be targeted by neutralizing antibodies (Memoli et al. 2016) . It is 274 important to note that the quality and relevance of protein array data is only as good as the 275 proteins printed. The use of reference monoclonal antibodies or plasma with known activity is 276 helpful to characterize the integrity of the protein reagents and printing conditions. Such 277 reference reagents can also serve to bridge data between different array print lots and stability as 278 donors suspected to be clinically protected from disease in a multiplexed and quantitative format 292 can help identify the best donor for antibody discovery. In this application it is valuable to have 293 functional neutralization assay data on the same sera, to correlate to binding. 294
Overall, we have provided new methods and qualification data to support applications 295 ELISA-Array assay format for infectious disease research. The key advantages we observed with 296 this technology included the passive coating in a protein stabilizing buffer, the low protein 297 reagent consumption with nanoliter printing, and the ability to perform quantitative analyses 298 using nearly the same workflow, reagents and lab equipment as used in the conventional ELISA. General instrument and experimental parameters 310
The Scienion sciFLEXARRAYER S12 instrument (Scienion AG, Berlin, Germany) has been 311 optimized for non-contact, piezo-acoustic dispensing of ultra-low volumes from an inert coated 312 glass capillary in a climate-controlled (temperature, dewpoint and humidity) environment, with 313 precise XYZ axis control and on-board camera and software for QC of each spot in the array. 314
We printed our arrays with the PDC70 type 3 nozzle (Scienion) due to its reduced 315 dispense volume and the specific hydrophobic coating optimized to improve the dispense 316 Protein stocks of recombinant proteins at 0.5 mg/mL in PBS or vaccine stocks were diluted 1:1 384 in D12 buffer, mixed by pipetting, transferred to a 384 well polypropylene plate 385 (sciSOURCEPLATE, Scienion), and centrifuged for 2 min at 1800xg ambient temperature to 386 eliminate debris or air bubbles. The pattern printed was a 6x6 spot array on each well, and each 387 protein or vaccine along with positive and negative controls was printed in triplicate, 3 spots per 388 well, with 3 drops printed per spot. A single lot of twelve 96-well plates were printed in one day, 389 and after overnight curing were either subject to the ELISA-Array assay the next day (plates 1-390 4), subject to temperature variations for one week (plates 5-7), or subject to varying incubation 391 times at 4ºC (plates 8-10). 392 393 Influenza ELISA-Array assay 394 Each 96-well printed array was printed according to the general instrument parameters described 395 above. All assay steps were performed at ambient temperature, incubations except the blocking 396 step were done with low agitation on a Titer Plate Shaker (Lab-line Instruments, Melrose, IL) 397 and washes were done using a BioTek ELx405 plate washer (Bio-Tek Instruments, Winooski, 398 VT). High agitation is avoided as it leads to comets around the spots, which interferes with 399 accurate spot definition during reading of absorbance intensity. Array plates were washed 1x 300 400 μL/well before immediately adding 200 μL/well of assay diluent (PBS, 0.5% BSA, 2% filtered 401 FBS, 0.2% BGG, 0.25% CHAPS, 5mM EDTA, 0.05% Polysorbate-20 and 0.05% ProClin 300, 402 pH 7.2) down the sides of the wells with a multichannel pipette. Plates were allowed to block for 403 1 hour. Human plasma was diluted 1/1000 in assay diluent and serially diluted ¼ for n=8 points. Data is from 3 inter-assay plates, with mean and SD shown. The IC 50 value for donor 1 plasma 462 against H7 is not shown because the titer was greater than the minimum 1/1000 dilution. week at ambient temperature , at 37 ºC and up to 8 weeks at 4 ºC. 470
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